© Copyright khedmeh Wall
CD Bioparticles is pleased to announce a suite of mRNA-LNP Vaccine Laboratory Process Development Assays.
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is pleased to announce a suite of comprehensive mRNA-LNP Vaccine Laboratory Process Development Assays. This latest addition to CD Bioparticles’ extensive service portfolio is specifically designed for the rapid and efficient development of mRNA-LNP vaccines.
The mRNA molecule is well known to the public through COVID-19 and the mRNA vaccine made from it is characterized by rapid blocking of pathogen mutation response, simple production process and scale-up. Detection and validation methods are the basis for quality control of mRNA LNP vaccines. Therefore, R&D companies should establish detection methods for the characteristics of mRNA, liposomes and formulations, as well as related impurities and other key quality attributes of mRNA vaccines to ensure the safety and efficacy of mRNA-LNP vaccines.
CD Bioparticles now offers a comprehensive portfolio of laboratory assays designed to support every stage of mRNA-LNP vaccine development. These assays provide researchers with the tools they need to optimize their vaccine formulations and ensure their safety and efficacy, accelerating the path to clinical trials and commercialization. In addition, CD Bioparticles’ team of scientific experts is available to work with researchers to develop custom assays to meet their specific needs.
CD Bioparticles mRNA-LNP vaccine assay portfolio encompasses a variety of methodologies, including Cellular Uptake Studies,mRNA Transfection Efficiency Study, In Vivo Biodistribution, Histopathological Studies, Biochemical Indicators Testing, and Detection of Antigen-Specific T Cells. By leveraging CD Bioparticles’ expertise in analysis and characterization, researchers can gain deeper insights into the properties and performance of their vaccines, enabling them to make informed decisions during the development process.
For example, in the mRNA Transfection Efficiency Study, DC2.4 cells are selected as the model cells for the infection experiment. After infecting the cells with GFP-mRNA-LNP, the intracellular GFP signal will be observed by fluorescence microscopy. CD Bioparticles can assist customers with immunostaining studies that not only examine the efficiency of mRNA transmission, but also help to identify the specific cell types that are transfected into a specific type of organ.
CD Bioparticles also offers In Vivo Biodistribution services. To visualize the distribution of LNP in an organism, the professionals use fluorescent dyes (e.g., DiD and DiO) and luciferase for labeling. Typically, luciferase mRNA (Luc-mRNA) is used as a model mRNA to follow the distribution of the expressed protein in vivo. After intravenous injection of Luc-mRNA-LNP, heart, liver, spleen, lung, kidney and lymph node tissues are isolated. The tissues will be visualized using the IVIS Spectral Live Image System. This will facilitate visualization studies of organ distribution and duration of protein activity production.
CD Bioparticles’ new mRNA-LNP assays are available to researchers and vaccine developers worldwide. The company is committed to providing cutting-edge technologies and services that support the advancement of biotechnology and improve human health. For more information about the services, please visit https://www.cd-bioparticles.net/services/bioparticles-analysiscand-characterization/mrna-lnp-vaccine-laboratory-process-development-assay.
About CD Bioparticles
CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.
CD Bioparticles proudly announces the launch of its new Functional Agarose Particles.
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles proudly announces the launch of its new Functional Agarose Particles designed for a variety of applications in the field of bioconjugation, isolation, and purification of biomacromolecules. These particles are ideal for researchers working in areas such as protein purification, antibody production, and nucleic acid isolation.
CD Bioparticles offers a range of functional agarose particles that can be used to covalently capture tagged biomolecules, such as tagged proteins, or to immobilize proteins and antibodies. They can also serve as hydrophobic chromatographic separation media, immobilized metal ion affinity chromatography resins, ion exchange chromatography resins, etc., which are suitable for conjugation of antibodies, streptavidin, enzymes and nucleic acids to activated agarose particles. They also play a critical role in the production of recombinant proteins and the purification of monoclonal antibodies. They are an important carrier tool in molecular biology and medical research, and their importance extends to biopharmaceutical and industrial engineering applications.
The new functional agarose particles are available with a variety of functional groups, including hydrophobic, ion exchange, and affinity chromatography groups. This allows researchers to choose the particles that best suit their specific needs. For example, the hydrophobic interaction chromatography (HIC) separation particles (functionalized with butyl, phenyl, octyl) can be utilized to separate proteins based on their hydrophobicity, while the immobilized metal affinity chromatography (IMAC) particles (functionalized with Al-NTA, Co2+, Co-IDA, Co-NTA, Cu-NTA, Fe-NTA, IDA, Ni2+, Ni-IDA, etc.) can be used to purify and enrich proteins such as His-tagged proteins.
In addition, agarose particles functionalized with DEAE, sulfopropyl, carboxymethyl, quaternary ammonium can be used as IEC resins with high ion exchange capacity and less nonspecific adsorption, which can be applied in the laboratory preparation of biomolecules such as proteins, nucleic acids and peptides. Activated agarose particles (functionalized with azide, alkyne, methyltetrazine, TCO, disulfide, etc.) can also be used for coupling of biomolecules.
The new functional agarose particles are available in a variety of sizes, ranging from 25 µm to 400 µm. In addition to their wide range of functionalities and sizes, these functional agarose particles offer a unique combination of properties that make them ideal for a broad range of applications, including excellent chemical stability, high yield and customizability. These particles can selectively bind to specific biomolecules, and this targeted binding capability streamlines the purification process, reducing time and effort for researchers.
CD Bioparticles’ Functional Agarose Particles are available in a variety of configurations to meet the specific needs of each research project. These particles offer superior efficiency and selectivity, enabling researchers to achieve faster and more accurate results. The company also offers custom bead development services to create particles tailored to unique applications. For more information, please visit https://www.cd-bioparticles.com/products/functional-agarose-particles-1065.html.
About CD Bioparticles
CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.